Head-to-head Superiority to High-dose Dulaglutide: Innovent'

Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints

Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints

prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Japan , Suzhou , Jiangsu , China , Beijing , Chinese , Innovent Biologics , Yang Wenying , Lixin Guo , Eli Lilly , Adimab Incyte , Department Of Endocrinology , Clinical Development Of Innovent , Prnewswire Innovent Biologics Inc , International Diabetes Federation , National Medical Products Administration , Md Anderson Cancer Center , Company Lilly , Linkedin , Drug Evaluation , Beijing Hospital , China Japan Friendship Hospital , Lei Qian , Vice President , Clinical Development , Res Clin ,